3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS
申请人:Taveras Arthur G.
公开号:US20090306079A1
公开(公告)日:2009-12-10
There are disclosed compounds of the formula
or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
Process of producing alpha-L-aspartyldipeptide amide derivatives
申请人:Ajinomoto Co., Ltd.
公开号:EP0719789A1
公开(公告)日:1996-07-03
The object of the present invention is to provide a useful process of producing α-L-aspartyldipeptide amide derivative.
The amino group of a L-aspartic acid β-alkylester is protected with acetoacetate or β-diketone. The resulting compound is converted into a mixed anhydride using an alkyl chloroformate, condensed with amino acid amide derivatives, and then hydrolyzed under acidic conditions to effect deprotection of the amino protective group and conversion of ester moiety into a carboxylic acid, whereby the target α-L-aspartyldipeptide amide derivatives are obtained.
3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
申请人:SCHERING CORPORATION
公开号:EP1818325A2
公开(公告)日:2007-08-15
There are disclosed compounds of the formula
or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.